G007-LK Tankyrase 1/2 Inhibitor: Precision Tool for Wnt/β-Catenin and APC-Mutant Cancer Research

Executive Summary: G007-LK is a potent, selective small-molecule inhibitor of tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2), with validated nanomolar IC₅₀ values in biochemical and cellular assays, including Wnt3a-induced HEK293 cells and APC-mutant colorectal cancer models [APExBIO]. It induces β-catenin degradation, stabilizes AXIN1/2, and inhibits tumor growth in vivo, as confirmed in COLO-320DM xenograft mouse models (Jia et al., 2017). G007-LK also modulates the Hippo pathway by downregulating YAP activity via AMOTL1/2 stabilization. The compound is insoluble in water but dissolves at ≥26.5 mg/mL in DMSO, requiring storage at -20°C as a solid. It is primarily used for dissecting Wnt/β-catenin and Hippo pathway function in APC mutation colorectal cancer and hepatocellular carcinoma research.

Biological Rationale

Tankyrases (TNKS1, TNKS2) are poly(ADP-ribose) polymerases that regulate diverse cellular processes, including Wnt/β-catenin signaling, telomere maintenance, cell cycle progression, and glucose metabolism (Jia et al., 2017). Dysregulation of tankyrase activity is implicated in cancer, especially in colorectal cancers with APC mutations and hepatocellular carcinoma, due to aberrant stabilization of β-catenin and altered Hippo pathway signaling. In many cancer types, upregulated tankyrase activity leads to increased poly(ADP-ribosyl)ation of AXIN1/2, promoting their proteasomal degradation and enabling nuclear β-catenin accumulation. This aberrant signaling supports tumor cell proliferation and survival. Tankyrase inhibition is therefore a validated approach to restore AXIN1/2 levels, trigger β-catenin degradation, and suppress oncogenic Wnt signaling [Related: G007-LK as a specific tankyrase inhibitor for Wnt signaling research]. G007-LK, as provided by APExBIO, offers high selectivity and potency for dissecting these pathways in relevant disease models.

Mechanism of Action of G007-LK tankyrase 1/2 inhibitor

G007-LK inhibits the catalytic activity of tankyrase 1 and tankyrase 2 by blocking auto-poly(ADP-ribosyl)ation, with IC₅₀ values of 46 nM (TNKS1) and 25 nM (TNKS2) in biochemical assays [APExBIO]. In cellular models, such as Wnt3a-induced HEK 293 cells, it suppresses Wnt signaling reporter ST-Luc with an IC₅₀ of 0.05 μM. This inhibition prevents PARylation-mediated degradation of AXIN1/2, stabilizing the β-catenin destruction complex. Consequently, cytosolic and nuclear β-catenin levels are reduced, leading to downregulation of Wnt target gene transcription. In APC-mutant colorectal cancer cells (e.g., SW480), G007-LK induces formation of degradasomes containing phosphorylated β-catenin, β-TrCP, and ubiquitin, directly promoting β-catenin ubiquitination and proteasomal clearance [Compare: systems-level perspective on β-catenin degradation]. G007-LK further modulates the Hippo pathway by stabilizing AMOTL1 and AMOTL2, negative regulators of YAP, resulting in decreased YAP protein levels and TEAD-mediated transcriptional activity (Jia et al., 2017).

Evidence & Benchmarks

• G007-LK inhibits TNKS1 and TNKS2 enzymatic activity in vitro with IC₅₀ values of 46 nM and 25 nM, respectively (APExBIO Product Data).
• In Wnt3a-stimulated HEK293 cells, G007-LK blocks Wnt signaling reporter activity (ST-Luc) with an IC₅₀ of 0.05 μM (APExBIO).
• In APC-mutant SW480 colorectal cancer cells, G007-LK induces degradasome formation and reduces cytosolic/nuclear β-catenin (Related article).
• In COLO-320DM xenograft mouse models, G007-LK administration reduces tumor growth, decreases TNKS1/2 and β-catenin protein, and stabilizes AXIN1/2 (Jia et al., 2017).
• G007-LK suppresses proliferation of hepatocellular carcinoma cell lines, reduces YAP protein levels, and upregulates AMOTL1/2 (Jia et al., 2017, Fig 2–4).
• Tankyrase inhibition synergizes with MEK and AKT inhibition to further decrease cancer cell proliferation (Jia et al., 2017, Table 1).
• G007-LK is soluble in DMSO at ≥26.5 mg/mL, insoluble in water and ethanol, and stable as a solid at -20°C (APExBIO).

Applications, Limits & Misconceptions

Applications:

• Dissection of Wnt/β-catenin signaling in APC-mutant cancer models.
• Mechanistic studies of Hippo–YAP/TAZ pathway crosstalk via AMOTL1/2 stabilization.
• Preclinical evaluation of β-catenin degradation and AXIN stabilization strategies.
• Validation of tankyrase as a therapeutic target in colorectal and hepatocellular carcinoma models (See: advanced crosstalk research using G007-LK).

Common Pitfalls or Misconceptions:

• G007-LK is not effective in tumors lacking Wnt/β-catenin pathway dependence.
• It does not directly inhibit β-catenin; activity is mediated via AXIN stabilization and tankyrase inhibition.
• Solubility is limited to DMSO; aqueous solutions are not viable and may result in precipitation.
• Long-term storage in solution may cause degradation; always store as a solid at -20°C.
• G007-LK does not inhibit all PARP family members; its selectivity is for TNKS1/2.

Workflow Integration & Parameters

Stock Preparation: Dissolve G007-LK at ≥26.5 mg/mL in DMSO. Use warming at 37°C or ultrasonic bath to aid dissolution. Avoid water and ethanol as solvents (APExBIO B5830 kit).

Storage: Store compound as solid at -20°C. Avoid repeated freeze-thaw cycles. Prepare fresh solutions for each experiment.

Cellular Assays: Use at nanomolar to micromolar concentrations (typically 0.01–10 μM), depending on cell line sensitivity and endpoint.

In Vivo Use: Dosing regimens should be based on prior studies (e.g., COLO-320DM models), with attention to formulation compatibility and DMSO levels (Jia et al., 2017).

Controls: Employ vehicle-only and unrelated PARP inhibitor controls to distinguish tankyrase-specific effects.

Interlinking Note: This article extends the mechanistic and translational scope discussed in 'G007-LK Tankyrase 1/2 Inhibitor: Mechanistic Precision and Translational Significance' by detailing workflow integration and critical pitfalls for experimental reproducibility.

Conclusion & Outlook

G007-LK, from APExBIO, is a benchmark tankyrase 1/2 inhibitor for precision modulation of the Wnt/β-catenin and Hippo-YAP signaling axes. Its nanomolar potency, validated efficacy in APC-mutant and hepatocellular carcinoma models, and well-characterized workflow integration make it a gold-standard tool for cancer biology research. Ongoing studies are expanding its use to dissect combinatorial pathway modulation and to validate tankyrase targeting in additional disease contexts. For further details and experimental guidance, visit the G007-LK tankyrase 1/2 inhibitor product page.